| Deal value | $24M |
|---|---|
| Share of market cap | 6.1% |
Key highlights
- Issuance of 20,338,974 shares of common stock at $1.18 per share
- Total aggregate gross proceeds reached approximately $24.0 million
- Closing finalized on October 16, 2026, after a two-week extension
- Capital raise follows a $100 million at-the-market offering agreement from August 2026
- Funding supports operations for a company with no current commercial product backlog
What Is the Capital Raise?
Indaptus Therapeutics finalized a private placement of common stock, issuing 20,338,974 shares at a price of approximately $1.18 per share. This closing concludes a process initiated via a Stock Purchase Agreement dated September 8, 2026. While originally scheduled for an earlier date, the company and purchasers agreed to extend the outside closing deadline to October 16, 2026, to ensure the full transfer of the $24.0 million aggregate purchase price. The transaction was conducted as a private placement, bypassing public markets to secure committed capital from specific institutional or accredited purchasers for the company's ongoing operational needs.
Strategic Rationale
This $24.0 million infusion represents a significant liquidity event for Indaptus as it manages its clinical-stage pipeline. The timing of the raise aligns with the company's broader capital management strategy, which included a $100 million at-the-market offering agreement established in late August 2026. By securing this private placement, Indaptus strengthens its balance sheet independently of public market volatility. The successful closing ensures the company can maintain its operational momentum heading into the final quarter of the year, providing a financial bridge as it approaches estimated third-quarter earnings reporting in mid-November.
Business Overview
Indaptus Therapeutics operates as a clinical-stage biotechnology company focused on developing novel immuno-oncology and anti-viral therapies. The company’s core technology is designed to activate both innate and adaptive immune responses to treat various cancers and chronic viral infections. Currently, Indaptus does not generate commercial sales or maintain a product backlog, a common profile for biotechnology firms in the research and development phase. Its primary focus remains on advancing its lead therapeutic candidates through clinical trials, which necessitates frequent access to capital markets to fund expensive laboratory work and human testing protocols.
Financial Context
Prior to this closing, Indaptus reported a cash runway extending into the second quarter of 2027. The addition of $24.0 million significantly expands this buffer, especially when viewed alongside previous funding rounds, such as the $12.0 million private placement completed in June 2026 and smaller rounds dating back to late 2025. The company’s market capitalization currently stands at approximately $394.4 million, with the stock showing recent volatility including a 23.85% gain over the past week offset by a 16.62% monthly decline. This capital raise provides essential stability as the company navigates the high-burn environment typical of the NASDAQ-listed healthcare sector.
Up 16.6% since our story on 20 Oct: $2.96 when we broke it → $3.45 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $2.73 |
|---|---|
| 20 Oct | $2.96 |
| 21 Oct | $3.16 |
| 22 Oct | $2.99 |
| 23 Oct | $3.16 |
| 26 Oct | $3.34 |
| 27 Oct | $3.31 |
| 28 Oct | $3.33 |
| 29 Oct | $3.34 |
| 30 Oct | $3.09 |
| 2 Nov | $3.50 |
| 3 Nov | $3.24 |
| 4 Nov | $3.30 |
| 5 Nov | $3.16 |
| 6 Nov | $3.32 |
| 9 Nov | $3.13 |
| 10 Nov | $2.90 |
| 11 Nov | $3.21 |
| 12 Nov | $3.15 |
| 13 Nov | $3.17 |
| 16 Nov | $3.45 |
| Date | Announcement | Amount |
|---|---|---|
| 08 Sep 2026 | Private placement of common stockSource: stocktitan.net | $24.0 Million |
| 28 Aug 2026 | At-the-market offering agreement for common stockSource: SEC filing | $100.0 Million |
| 17 Jun 2026 | Private placement of common stockSource: morningstar.com | $12.0 Million |
| 22 Dec 2025 | Private placement of Series AA and Series AAA convertible preferred stockSource: SEC filing | $6.0 Million |
| 01 Jul 2025 | Private placement of convertible promissory notes and warrantsSource: globenewswire.com | $3.4 Million |
| 13 Jun 2025 | Private placement of convertible promissory notes and warrantsSource: firstwordpharma.com | $2.3 Million |
| Share price | $2.96 |
|---|---|
| Market cap | $394M |
| 1-month price change | -16.62% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Indaptus Therapeutics, Inc. announcing the closing of a $24.0 million private placement.
Track Indaptus Therapeutics, Inc. live
Get the next Indaptus Therapeutics, Inc. SEC filing seconds after it lands.



